ProShare Advisors LLC Sells 8,502 Shares of Bristol Myers Squibb Company $BMY

ProShare Advisors LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 384,166 shares of the biopharmaceutical company’s stock after selling 8,502 shares during the quarter. ProShare Advisors LLC’s holdings in Bristol Myers Squibb were worth $17,326,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Gateway Investment Advisers LLC increased its holdings in Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares during the period. CWA Asset Management Group LLC grew its position in shares of Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after buying an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC increased its stake in shares of Bristol Myers Squibb by 24.6% during the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after buying an additional 11,690 shares during the period. Railway Pension Investments Ltd raised its holdings in shares of Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares in the last quarter. Finally, Stephens Inc. AR lifted its stake in Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Citigroup lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday. Eight research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $60.82 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The business’s fifty day simple moving average is $54.82 and its 200-day simple moving average is $49.20. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The company has a market cap of $123.81 billion, a PE ratio of 17.63, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the firm earned $1.67 earnings per share. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.